



Investing in HealthTech Expansion

ALIVE is a mid-late stage HealthTech fund leveraging an exclusive ecosystem of strategic partners, to support and accelerate portfolio companies in their clinical and commercial expansion

Management Team



Prof. Rafael Beyar
Managing General Partner

Former Director and CEO of Rambam Health Care Campus



Michel Habib
Managing General Partner

Senior Biomed Venture Capitalist, Former CEO of Hadasit Bio Holdings



Prof. Ari Shamiss
Managing General Partner

Former CEO of Assuta Medical Centers & Director of Sheba General Hospital



Dudi Klein
Managing Partner

Former Head of Ventures and Innovation, Assuta Medical Centers

Strategic Partners



Investment Focus

Surgical
Robotics
Implanted Devices
Minimal Invasive
Drug Delivery

Diagnostics
Imaging
Sensors
Bioinformatics

Telemedicine
Artificial Intelligence
Remote Patient
Management
Healthcare IT
Cyber Security

ALIVE's Ecosystem Offers:

Access to KOLs
Clinical trials sites
>3.5 Million patients & EMRs

Clinical need validation
Product validation
Business model verification

Exit strategy development
Exposure to potential anchor clients
Follow-on investments

Israel's Life Sciences Industry Sub-Sectors


Industry

1,900
active life science companies¹

>80%
are HealthTech companies

Exits

77%
of Life Science exits are in HealthTech¹



The Israeli HealthTech Opportunity

Israeli investors have been focusing on Seed and Early-stage investments for decades, increasing the gap between the progress of the HealthTech industry and the financial sector.

ALIVE bridges this widening gap by delivering value to its companies at every stage of the investment process, from product validation to patient bedside distribution.



Our Portfolio



OD Medisafe

INNOVALVE

Cynerio



Fund Terms & Metrics

Fund Size	\$150M target
Initial Closing	\$50M July 2020
GP & Anchors Commitment	\$43M
Carried Interest	20%, 8% Hurdle + Catch Up
Investment Period	4 years (from final closing)
Management Fees	2%

Scope	\$5-10M lead investor \$10-30M rounds
Board	Active Board Membership
Target Returns	> 5X returns in < 5 years
Equity Sought	10% to 20% per company
Portfolio	12-15